ETAHX — Eventide Healthcare & Life Sciences Fund
Data updated: 2026-05-29
ETAHX — Eventide Healthcare & Life Sciences Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $1.59B AUM · 1.56% expense ratio · 60.2% 1-yr return. From SEC regulatory filings.
ETAHX Fund Overview
ETAHX — Eventide Healthcare & Life Sciences Fund is a US mutual fund managed by Mutual Fund Series Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Mutual Fund Series Trust
- Category: United States Health Care Equity
- Assets under management: $1.59B
- 1-year return: 60.2%
- Ticker: ETAHX
- SEC CIK: 0001355064
- SEC series ID: S000039514
- Share class ID: C000121707
ETAHX Holdings
Top 10 holdings of Eventide Healthcare & Life Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Guardant Health Inc | 4.07% |
| Mirum Pharmaceuticals Inc. | 4.02% |
| Insmed Inc | 3.78% |
| US Bank Mmda | 3.65% |
| BeLite Bio Inc | 3.30% |
| Kymera Therapeutics Inc | 3.28% |
| Vaxcyte Inc | 3.03% |
| Apogee Therapeutics Inc. | 2.96% |
| Ionis Pharmaceuticals, Inc. | 2.72% |
| Argenx SE | 2.26% |
ETAHX Portfolio Allocation
Asset-class allocation of Eventide Healthcare & Life Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 93.5% |
| Cash & Equivalents | 5.5% |
| Derivatives | 0.3% |
ETAHX Performance
Total returns for ETAHX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -4.8% |
| 1 year | 60.2% |
| 3 years (annualised) | 14.6% |
| 5 years (annualised) | 1.3% |
ETAHX Risk Information
Risk metrics for ETAHX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 20.7%
ETAHX Costs and Fees
ETAHX costs about $156 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.56%
- Gross expense ratio: 1.56%
- Portfolio turnover: 41%
- Brokerage commissions: 13.49 bps of average net assets (SEC N-CEN)
ETAHX Cashflows
Over the 12 months to 2026-03, Eventide Healthcare & Life Sciences Fund had net outflows of $142.48M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$9.50M |
| 2026-02 | $6.21M |
| 2026-01 | −$17.79M |
| 2025-12 | −$2.88M |
| 2025-11 | −$7.59M |
| 2025-10 | $5.81M |
ETAHX Debt Constituents
Largest debt holdings of Eventide Healthcare & Life Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Biosplice Therapeutics Inc. Series C | 0.01% |
ETAHX Prospectus and SEC Filings
Official Eventide Healthcare & Life Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.